Tianyin Pharmaceutical Co, Inc. Receives GMP For Tablets Formulation In Early July
CHENGDU, China, July 7, 2014 /PRNewswire/ -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API), today announced that the Company has received the Good Manufacturing Practice (GMP) certification under certificate number Chuan K0592, valid until December 31, 2015 for its tablets manufacturing division. TPI will start production of the tablets formulation immediately and expect the resumption of full production capacity within 30 days.
In April 2014, TPI announced that regulatory quality and pricing tests were conducted by the China Food and Drug Administration (CFDA) of Sichuan province, which resulted in the Company's GMP certificate being temporarily administrated by the provincial CFDA. As a result, production and sale of certain of the Company's products were temporarily halted, pending the results of quality and pricing tests. In early May, TPI received the renewed GMP certificate for both of its Chengdu Tianyin's pre-extraction facility in the city of Chengdu and formulation facility at Longquan County of Chengdu, valid until December 31, 2015, under certificate numbers of "Chuan J0461" and "Chuan K0592." Normal manufacturing and sales for most of the Company's products resumed, except for the tablets formulation division which was scheduled for further inspection by the provincial CFDA staff. TPI passed the inspection on its tablets formulation division in mid June.
About TPI
Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 10 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. For more information about TPI, please visit: http://www.tianyinpharma.com
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
For more information, please visit: http://www.tianyinpharma.com, or email: ir@tpi.asia
Tel: +86-28-8551-6696 (Chengdu, China)
Address:
Tianyin Pharmaceutical Inc.
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China
SOURCE Tianyin Pharmaceutical Co., Inc.